Advanced Enzyme Technologies Limited has released its Earnings Presentation for the quarter ended June 30, 2026. The presentation covers key financial highlights, including consolidated year-over-year and quarter-over-quarter results for Revenue, EBITDA, and PAT. It also details performance across various business segments and geographical regions, offering insights into the company’s strategic focus and future outlook.
Advanced Enzyme Technologies Presents Q1 FY27 Financials
Advanced Enzyme Technologies Limited has released its comprehensive Earnings Presentation for the quarter ending June 30, 2026. The document details the company’s financial performance, strategic initiatives, and market positioning. The presentation is intended for public dissemination and provides stakeholders with an update on the company’s progress.
Key Financial Highlights (Q1 FY27 vs. Q1 FY26 – Year-over-Year)
The results summary indicates a 2% growth in revenue, reaching ₹1,898 million compared to ₹1,859 million in Q1 FY26. However, EBITDA saw a 10% de-growth to ₹510 million from ₹564 million, and PAT decreased by 5% to ₹386 million from ₹404 million. EBITDA margin stood at 27% and PAT margin at 20% for Q1 FY27.
Quarter-over-Quarter Performance (Q1 FY27 vs. Q4 FY26)
On a sequential basis, revenue grew by 7% to ₹1,898 million in Q1 FY27 from ₹2,034 million in Q4 FY26. EBITDA experienced a 19% de-growth to ₹510 million from ₹632 million, and PAT decreased by 15% to ₹386 million from ₹453 million.
Segmental Performance
The presentation breaks down performance by key segments:
- Human Nutrition: Contributed 60% of revenue, with a 7% de-growth year-on-year to ₹1,139 million.
- Animal Nutrition: Contributed 13% of revenue, with a 3% de-growth year-on-year to ₹252 million.
- Industrial Bio-Processing: Contributed 16% of revenue, with a significant 30% year-on-year growth to ₹306 million. Food business grew 51% YoY, while Non-Food de-grew 30% YoY.
- Specialized Manufacturing: Contributed 11% of revenue, outperforming with a 41% year-on-year growth to ₹200 million.
Geographical Performance
Geographical performance shows:
- India: 49% of revenue, with a 4% decrease year-on-year.
- Americas: 29% of revenue, with a 3% decrease year-on-year.
- Europe: 7% of revenue, with a notable 44% increase year-on-year.
- Asia (ex-India): 13% of revenue, with a 37% increase year-on-year.
- Rest of the World: 2% of revenue, with a 15% decrease year-on-year.
Profit & Loss Summary (Consolidated)
For Q1 FY27, Income from Operations was ₹1,898 million, with Expenses at ₹1,487 million. Net Profit for the period stood at ₹386 million, with Earnings Per Share at ₹3.31. The presentation also includes comparative data for Q4 FY26, Q1 FY26, FY26 Audited, and FY25 Audited figures, along with Y-o-Y and Q-o-Q percentage changes.
Financial Performance Over Years (FY22-FY26)
The document highlights strong financial performance trends for FY26, with Revenue from Operations at ₹7,458 million, EBITDA at ₹2,291 million (18% growth), and PAT at ₹1,736 million (30% growth). Key ratios such as EBITDA & PAT Margins, PBT & PBT Margin, ROE & ROCE, and Net Debt to Equity are also detailed for the period FY22-FY26.
Balance Sheet and Investment Case
The consolidated balance sheet for FY26 shows Total Assets of ₹18,388 million and Total Equity and Liabilities also at ₹18,388 million. The presentation further elaborates on ‘What Makes AETL a Unique Investment Case?’, citing factors like strong R&D capabilities, inherent diversification, robust financial performance, specialized business with high entry barriers, integrated presence across the enzyme value chain, and significant focus on international markets.
Future Growth Drivers and Focus Areas
Future growth drivers include continued investment in R&D, broadening geographical presence, and inorganic expansion through acquisitions. Key focus areas going ahead are Animal Nutrition, Bio-Catalysis, Probiotics, and Baking, with strategic plans to expand market reach and product offerings.
Shareholders Information
Shareholder data includes Market Capitalization of ₹34,433 million and Shares Outstanding of 111.98 million. Top institutional holders and the shareholding pattern are also provided as of June 30, 2026.
Source: BSE
